<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">879268</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.879268</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Deciphering the Active Compounds and Mechanisms of HSBDF for Treating ALI <italic>via</italic> Integrating Chemical Bioinformatics Analysis</article-title>
<alt-title alt-title-type="left-running-head">Wang et al.</alt-title>
<alt-title alt-title-type="right-running-head">HSBDF Treats ALI</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yanru</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Xiaojie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1007240/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fan</surname>
<given-names>Qin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Chenghao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1628120/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yongfeng</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Qingfeng</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jiawei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xiuzhu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Siyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1013422/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Ling</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/986684/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ling</surname>
<given-names>Jia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Chaoxin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Qianqian</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1400767/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Yongqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1200167/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Gansu University Key Laboratory for Molecular Medicine and Chinese Medicine Prevention and Treatment of Major Diseases, Gansu University of Chinese Medicine</institution>, <addr-line>Lanzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>College of Pharmacy, Gansu University of Chinese Medicine</institution>, <addr-line>Lanzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Gansu University of Chinese Medicine</institution>, <addr-line>Lanzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Institute of Modern Physics, Chinese Academy of Sciences</institution>, <addr-line>Lanzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Chronic Disease Research Center, Medical College, Dalian University</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Key Laboratory of Dunhuang Medical and Transformation, Ministry of Education of The People&#x2019;s Republic of China</institution>, <addr-line>Lanzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1118635/overview">Palanisamy Subramanian</ext-link>, Gangneung&#x2013;Wonju National University, South Korea</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/904289/overview">Debasish Kumar Dey</ext-link>, University of Oklahoma, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1190002/overview">C. Gopi Mohan FRSC</ext-link>, Amrita Vishwa Vidyapeetham University, India</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Qianqian Wang, <email>wangqianqian@dlu.edu.cn</email>; Yongqi Liu, <email>liuyongqi73@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Respiratory Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>879268</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wang, Jin, Fan, Li, Zhang, Wang, Wu, Li, Liu, Wang, Wang, Li, Ling, Li, Wang and Liu.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Jin, Fan, Li, Zhang, Wang, Wu, Li, Liu, Wang, Wang, Li, Ling, Li, Wang and Liu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The Huashi Baidu Formula (HSBDF), a key Chinese medical drug, has a remarkable clinical efficacy in treating acute lung injury (ALI), and it has been officially approved by the National Medical Products Administration of China for drug clinical trials. Nevertheless, the regulated mechanisms of HSBDF and its active compounds in plasma against ALI were rarely studied. Based on these considerations, the key anti-inflammatory compounds of HSBDF were screened by molecular docking and binding free energy. The key compounds were further identified in plasma by LC/MS. Network pharmacology was employed to identify the potential regulatory mechanism of the key compounds in plasma. Next, the network pharmacological prediction was validated by a series of experimental assays, including CCK-8, EdU staining, test of TNF-&#x3b1;, IL-6, MDA, and T-SOD, and flow cytometry, to identify active compounds. Molecular dynamic simulation and binding interaction patterns were used to evaluate the stability and affinity between active compounds and target. Finally, the active compounds were subjected to predict pharmacokinetic properties. Molecular docking revealed that HSBDF had potential effects of inhibiting inflammation by acting on IL-6R and TNF-&#x3b1;. Piceatannol, emodin, aloe-emodin, rhein, physcion, luteolin, and quercetin were key compounds that may ameliorate ALI, and among which, there were five compounds (emodin, aloe-emodin, rhein, luteolin, and quercetin) in plasma. Network pharmacology results suggested that five key compounds in plasma likely inhibited ALI by regulating inflammation and oxidative damage. Test performed <italic>in vitro</italic> suggested that HSBDF (0.03125&#xa0;mg/ml), quercetin (1.5625&#xa0;&#x3bc;M), emodin (3.125&#xa0;&#x3bc;M), and rhein (1.5625&#xa0;&#x3bc;M) have anti-inflammatory function against oxidative damage and decrease apoptosis in an inflammatory environment by LPS-stimulation. In addition, active compounds (quercetin, emodin, and rhein) had good development prospects, fine affinity, and stable conformations with the target protein. In summary, this study suggested that HSBDF and its key active components in plasma (quercetin, emodin, and rhein) can decrease levels of pro-inflammatory factors (IL-6 and TNF-&#x3b1;), decrease expression of MDA, increase expression of T-SOD, and decrease cell apoptosis in an inflammatory environment. These data suggest that HSBDF has significant effect on anti-inflammation and anti-oxidative stress and also can decrease cell apoptosis in treating ALI. These findings provided an important strategy for developing new agents and facilitated clinical use of HSBDF against ALI.</p>
</abstract>
<kwd-group>
<kwd>Traditional Chinese medicine</kwd>
<kwd>Huashi Baidu formula</kwd>
<kwd>acute lung injury</kwd>
<kwd>inflammation</kwd>
<kwd>oxidative stress</kwd>
<kwd>apoptosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Acute lung injury (ALI), an early stage of acute respiratory distress syndrome (ARDS) (<xref ref-type="bibr" rid="B32">Sun et al., 2020</xref>), can be caused by various intrapulmonary and extrapulmonary pathogenic factors, such as COVID-19 (<xref ref-type="bibr" rid="B41">Yang et al., 2020</xref>). HSBDF was recommended to treat ALI at the later stages of COVID-19 by the National Health Commission of the People&#x2019;s Republic of China (NHC) (<xref ref-type="bibr" rid="B34">Wang and Qi, 2020</xref>) and has been officially approved by the National Medical Products Administration of China for drug clinical trials due to remarkable clinical efficacy. However, its active compounds in plasma and its regulatory mechanisms are not clear yet.</p>
<p>Inflammatory cytokine storm is a characteristic of ALI. Previous studies indicated that interleukin 6 (IL-6) and tumor necrosis factor-&#x3b1; (TNF-&#x3b1;) were key cytokines involved in the pathological process of ALI (<xref ref-type="bibr" rid="B9">Gao et al., 2019</xref>). IL-6 and TNF-&#x3b1; were considered critical targets to prevent inflammation in treating ALI.</p>
<p>Molecular docking and network pharmacology are widely used in researching the material basis and mechanism of TCM in the prevention and treatment of disease (<xref ref-type="bibr" rid="B43">Yu R et al., 2020</xref>; <xref ref-type="bibr" rid="B44">Yu S et al., 2020</xref>; <xref ref-type="bibr" rid="B3">Chen et al., 2021a</xref>; <xref ref-type="bibr" rid="B4">Chen et al., 2021b</xref>; <xref ref-type="bibr" rid="B5">Chen et al., 2021c</xref>; <xref ref-type="bibr" rid="B36">Wang et al., 2021</xref>). However, owing to the complexity of TCM and the compounds in plasma remained elusive, it is necessary to make full use of the LC/MS method to conduct the research on active compounds of HSBDF in plasma in treating ALI. Therefore, based on IL-6 and TNF-&#x3b1;, this study aimed to uncover the regulatory mechanisms of HSBDF and its active compounds in plasma against ALI by the integrated strategy of molecular docking, LC/MS, network pharmacology, and <italic>in vitro</italic> approaches, which provide the basic data for further scientific research and clinical use of HSBDF in treating ALI.</p>
</sec>
<sec id="s2">
<title>2 Materials and Methods</title>
<sec id="s2-1">
<title>2.1 Materials and Reagents</title>
<p>
<italic>Ephedra sinica</italic> (Shengmahuang, No. 190701), <italic>Agastache rugosus</italic> (Huoxiang, No. 200803003), Gypsum Fibrosum (Shengshigao, No. 201001), <italic>Semen armeniacae amarum</italic> (Kuxingren, No. 202012002), <italic>Rhizoma Pinelliae Preparata</italic> (Fabanxia, No. D2012128), <italic>Magnolia officinalis</italic> (Houpo, No. 202009002), <italic>Atractylodes lancea</italic> (Cangzhu, No. 20210120), <italic>Fructus tsaoko</italic> (Caoguo, No. 20180919), <italic>Poria cocos</italic> (Fuling, JZ2105009), <italic>Astragalus membranaceus</italic> (Shenghuangqi, No. 20210108), <italic>Radix Paeoniae Rubra</italic> (Chishao, No. 2103012), <italic>Lepidium apetalum</italic> (Tinglizi, No. 20210206), <italic>Rheum officinale</italic> (Shengdahuang, No. JZ2012020), and <italic>Glycyrrhiza uralensis</italic> (Gancao, No. 20210201) were obtained from The Affiliated Hospital of Gansu University of Chinese Medicine (Lanzhou, China) at an accurate prescription dose, and their equality control adhered to the specifications and test procedures as described in the Pharmacopoeia of the People&#x2019;s Republic of China (2020). HSBDF was decocted with water (1:8, w/v) for 60&#xa0;min. The aqueous solutions were obtained by merging, filtrating, and concentrating to 1.23&#xa0;g/ml. The extracts were kept at 4&#xb0;C for preparation of a lyophilized powder for further oral administration to rats and preparation of lyophilized powder.</p>
<p>Methanol and acetonitrile (HPLC pure grade) were purchased from MREDA (MREDA, China), and formic acid of the same grade was provided by Thermo Fisher (Thermo Fisher, Waltham, MA, United States). Ultrapure water was obtained from Wahaha (Wahaha, China) and used throughout the study. Quercetin, luteolin, piceatannol, emodin, rhein, aloe-emodin, and physcion were all purchased from Baoji Herbest Bio-Tech Co., Ltd. (Herbest Bio-Tech, China). The purity of all reference standards was more than 98%. Other reagents of analytical grade were obtained from commercial sources.</p>
<p>LPS, cell counting kit-8, and Click-iT EdU-488 cell proliferation kit were purchased from Solarbio (Beijing, China), Yeasen (Yeasen Biotech, China), and Servicebio (Wuhan, China), respectively. DME/F-12, 1,640, and PBS were obtained from HyClone (HyClone, Logan, UT, United States). Annexin V&#x2212;FITC/PI apoptosis detection kit was provided by Meilunbio (Dalian, China). MDA (20211202) and T-SOD (20211201) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). ELISA kits including TNF-&#x3b1; (2111H27) and IL-6 (2111H35) were purchased from Jiangsu Feiya Biotechnology Co., Ltd. (Jiangsu, China).</p>
</sec>
<sec id="s2-2">
<title>2.2 Virtual Screening and Pharmacokinetic Prediction</title>
<sec id="s2-2-1">
<title>2.2.1 Compounds of Huashi Baidu Formula</title>
<p>The compounds were collected from the traditional Chinese medicine systems pharmacology (TCMSP, <ext-link ext-link-type="uri" xlink:href="https://www.tcmspw.com/tcmsp.php">https://www.tcmspw.com/tcmsp.php</ext-link>) (<xref ref-type="bibr" rid="B29">Ru et al., 2014</xref>) database and Traditional Chinese Medicines Integrated Database (TCMID, <ext-link ext-link-type="uri" xlink:href="http://119.3.41.228:%208000/tcmid/">http://119.3.41.228: 8000/tcmid/</ext-link>) (<xref ref-type="bibr" rid="B40">Xue et al., 2013</xref>). Meanwhile, compounds of each herb were supplemented through a literature search in the PubMed database (<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</ext-link>). A total of 1,613 compounds were retrieved for 13 herbs, among which there were <italic>E. sinica</italic> (363), <italic>S. armeniacae amarum</italic> (113), <italic>L. apetalum</italic> (68), <italic>R. paeoniae rubra</italic> (119), <italic>A. rugosus</italic> (94), <italic>M. officinalis</italic> (139), <italic>A. lancea</italic> (49), <italic>F. tsaoko</italic> (59), <italic>Astragalus membranaceus</italic> (87), <italic>Glycyrrhiza uralensis</italic> (280), <italic>R. officinale</italic> (92), <italic>P. cocos</italic> (34), and <italic>R. Pinelliae Preparata</italic> (116). It was worth noting that Gypsum Fibrosum is a mineral drug, and its main composition was CaSO<sub>4</sub>&#x2022;2H<sub>2</sub>O. Therefore, its mechanism of action was not included in this study.</p>
</sec>
<sec id="s2-2-2">
<title>2.2.2 3D Structures of Protein</title>
<p>The 3D structures of IL-6R (PDB ID: 1P9M) (<xref ref-type="bibr" rid="B14">Ho et al., 2009</xref>), TNF-&#x3b1; (PDB ID: 2AZ5) (<xref ref-type="bibr" rid="B13">He et al., 2005</xref>), PIK3R1 (PDB ID: 4I6J) (<xref ref-type="bibr" rid="B39">Xing et al., 2013</xref>), SRC (PDB ID: 4U5J) (<xref ref-type="bibr" rid="B7">Duan et al., 2014</xref>), AKT1 (PDB ID: 4EKL) (<xref ref-type="bibr" rid="B23">Lin et al., 2012</xref>), TP53 (PDB ID: 5LAY) (<xref ref-type="bibr" rid="B12">Gollner et al., 2016</xref>), and PIK3CA (PDB ID: 7K6M) (<xref ref-type="bibr" rid="B6">Cheng et al., 2021</xref>) were downloaded from the RCSB Protein Data Bank (PDB, <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>).</p>
</sec>
<sec id="s2-2-3">
<title>2.2.3 Molecular Docking and Binding Free Energy Calculation</title>
<p>3D structures of protein in 2.2.2 were preprocessed by Protein Preparation Wizard. The compounds in 2.2.1 were prepared by the LigPrep module (<xref ref-type="bibr" rid="B31">Sheikh et al., 2018</xref>). A total of 1,613 compounds were docked with IL-6R and TNF-&#x3b1; by the Glide standard docking precision method (SP) in Schr&#x151;dinger 2020-4. The corresponding low-energy conformation was obtained by MMFFs. Next, epik28 (<xref ref-type="bibr" rid="B26">Manchester et al., 2010</xref>) used a pH value of 7.0 &#xb1; 2.0 to conditionally allocate the ionization state and perform docking calculations.</p>
<p>The binding free energy was used to evaluate the affinity between the ligand and receptor. Lower binding free energy indicates a higher affinity or catalytic activity (<xref ref-type="bibr" rid="B37">Wu et al., 2009</xref>). In this study, MM/GBSA in the prime program was used to estimate binding energy (<xref ref-type="bibr" rid="B15">Hou et al., 2011</xref>). The formula is: DG bind &#x3d; E_complex (minimized)&#x2014;E_ligand (minimized)-E_receptor (minimized).</p>
</sec>
<sec id="s2-2-4">
<title>2.2.4 Molecular Dynamic Simulation and Binding Interaction Pattern Analysis</title>
<p>The initial structures of the protein complex with active compounds (emodin, rhein, and quercetin) were obtained from molecular docking. To further determine the stability of rhein and quercetin with IL-6R and rhein and emodin with the TNF-&#x3b1; complex in a simulated physiological solvent system, we used the Desmond module of Schr&#xf6;dinger to carry out molecular dynamic simulation. The molecular system was solvated with crystallographic water (TIP3P) for a 10-&#xc5; buffer region under orthorhombic periodic boundary conditions. The system charges were neutralized by adding Na<sup>&#x2b;</sup> and Cl<sup>&#x2212;</sup>. The molecular system was solvated with crystallographic water (TIP3P) molecules under orthorhombic periodic boundary conditions for a 10&#xa0;&#xc5; buffer region. The system charges were neutralized by adding Na<sup>&#x2b;</sup> and Cl<sup>&#x2212;</sup>. The OPLS_2005 force field was used for energy calculation. After this, an ensemble (NPT) of Nose&#x2013;Hoover thermostat and barostat was applied to maintain the constant temperature (300&#xb0;K) and pressure (1&#xa0;bar) of the systems, respectively. The complex structural dynamic simulation for the best complex was carried out with an NPT ensemble for 50&#xb0;ns, and the trajectory was set at an interval of 10&#xb0;ps. The RMSD (root mean square distance) was used to compare the prediction error in disparate models of specific data sets and protein&#x2013;ligand contacts with the timeline. In addition, the 3D binding interaction pattern of active compounds with protein was visualized by PyMOL.</p>
</sec>
<sec id="s2-2-5">
<title>2.2.5 Pharmacokinetic Prediction of Active Compounds</title>
<p>The parameters of absorption, distribution, metabolism, excretion, and toxicity (ADMET) of emodin, rhein, and quercetin were calculated by using the ProTox-II data platform. In addition, active compounds that conformed to Lipinski&#x2019;s rule were predicted by the QikProp module of Schr&#xf6;dinger.</p>
</sec>
</sec>
<sec id="s2-3">
<title>2.3 LC/MS Analysis</title>
<sec id="s2-3-1">
<title>2.3.1 Animals and Drug Administration</title>
<p>A total of six male Sprague-Dawley rats (200 &#xb1; 20&#xb0;g, SPF grade) were purchased from the Laboratory Animal Center of Gansu University of Chinese Medicine (Lanzhou, China) with license number: SCXK (gan) 2020-0001. All animals were housed in the Laboratory Animal Center of Gansu University of Chinese Medicine [animal license number: SCXK (gan) 2020-0009]. The rats were fed standard rodent chow and water <italic>ad libitum</italic> in a house with a 12&#xa0;h light/dark cycle (temperature and humidity of 23&#xb0;C &#xb1; 2&#xb0;C and 60% &#xb1; 5%, respectively) for 10&#xa0;days to adapt to the experimental environment. The experimental protocol, approved by the Committee for Ethics in the Laboratory Animal Center of Gansu University of Chinese Medicine (number: 2021-182), was conducted in strict accordance with the ethical principles in animal research.</p>
</sec>
<sec id="s2-3-2">
<title>2.3.2 Instrumentations and Analytical Conditions</title>
<p>The triple quadrupole LC/MS system consisted of an ExionLC (SCIEX, Framingham, MA, United States) and a SCIEX Triple Quad 5,500&#x2b; (SCIEX, Framingham, MA, United States) equipped with an ESI source. The chromatographic separation was achieved on a Kinetex C18 column (100&#xa0;mm &#xd7; 2.1&#xa0;mm, 2.6&#xa0;&#xb5;m, Kinetex&#xae; C18, Phenomenex, United States). The water (containing 0.2% formic acid, solvent A) acetonitrile, and methanol (1:1, v: v, solvent B) system was used as the mobile phase. Analysis was achieved by gradient elution at a flow rate of 0.3&#xa0;ml/min. The gradient elution program was: 0&#x2013;2&#xa0;min, 10% B; 2&#x2013;5&#xa0;min, 10%&#x2013;40% B; 5&#x2013;15&#xa0;min, 40%&#x2013;50% B; 15&#x2013;30&#xa0;min, 50%&#x2013;55% B; 30&#x2013;50&#xa0;min, 55%&#x2013;66% B; 50&#x2013;63&#xa0;min, 66%&#x2013;80% B; and 63&#x2013;73&#xa0;min, 80%&#x2013;100% B. The column and auto-sampler tray temperatures were kept at 30&#xb0;C and 4&#xb0;C, respectively. The injection volume was 2&#xa0;&#x3bc;l. All analytes were quantified using multiple reaction monitoring (MRM) detection in the negative ion mode. The parameters of MRM are shown in <xref ref-type="table" rid="T1">Table 1</xref>. Other main working parameters were as follows: curtain gas (CUR), ion source gas1 (GS1), and ion source gas2 (GS2) were set at 35, 50, and 50&#xa0;psi, respectively. IonSpray (IS) voltage, &#x2212;4,500&#xa0;V; temperature (TEM), 550&#xb0;C.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Ions and fragmentations used in the MRM mode for seven compounds.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound</th>
<th align="center">MRM fragment</th>
<th align="center">Dwell time (msec)</th>
<th align="center">DP (volts)</th>
<th align="center">DP (volts)</th>
<th align="center">Retention time (min)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left">Piceatannol</td>
<td align="char" char="/">243.1/159</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;122</td>
<td align="char" char=".">&#x2212;36.7</td>
<td rowspan="2" align="char" char=".">5.10</td>
</tr>
<tr>
<td align="char" char="/">243.1/201.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;122.42</td>
<td align="char" char=".">&#x2212;31.26</td>
</tr>
<tr>
<td rowspan="2" align="left">Emodin</td>
<td align="char" char="/">269/225</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;117.21</td>
<td align="char" char=".">&#x2212;39.04</td>
<td rowspan="2" align="char" char=".">22.39</td>
</tr>
<tr>
<td align="char" char="/">269/241</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;104.02</td>
<td align="char" char=".">&#x2212;39.26</td>
</tr>
<tr>
<td rowspan="3" align="left">Aloe-emodin</td>
<td align="char" char="/">269.1/240</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;122.91</td>
<td align="char" char=".">&#x2212;30.76</td>
<td rowspan="3" align="char" char=".">12.00</td>
</tr>
<tr>
<td align="char" char="/">269.1/183.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;122.94</td>
<td align="char" char=".">&#x2212;44.76</td>
</tr>
<tr>
<td align="char" char="/">271.3/239.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;89.09</td>
<td align="char" char=".">&#x2212;51.73</td>
</tr>
<tr>
<td rowspan="3" align="left">Rhein</td>
<td align="char" char="/">283.1/239</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;49.87</td>
<td align="char" char=".">&#x2212;24.24</td>
<td rowspan="3" align="char" char=".">14.77</td>
</tr>
<tr>
<td align="char" char="/">283.1/183.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;49.93</td>
<td align="char" char=".">&#x2212;42.03</td>
</tr>
<tr>
<td align="char" char="/">283.1/211.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;50.76</td>
<td align="char" char=".">&#x2212;35.1</td>
</tr>
<tr>
<td rowspan="3" align="left">Physcion</td>
<td align="char" char="/">283.2/240.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;93.21</td>
<td align="char" char=".">&#x2212;37.75</td>
<td rowspan="3" align="char" char=".">35.36</td>
</tr>
<tr>
<td align="char" char="/">283.2/211.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;68.93</td>
<td align="char" char=".">&#x2212;47</td>
</tr>
<tr>
<td align="char" char="/">283.2/183</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;66.86</td>
<td align="char" char=".">&#x2212;56</td>
</tr>
<tr>
<td rowspan="2" align="left">Luteolin</td>
<td align="char" char="/">285.1/133.1</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;92.87</td>
<td align="char" char=".">&#x2212;45.01</td>
<td rowspan="2" align="char" char=".">7.62</td>
</tr>
<tr>
<td align="char" char="/">285.1/151</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;118.83</td>
<td align="char" char=".">&#x2212;35.17</td>
</tr>
<tr>
<td rowspan="2" align="left">Quercetin</td>
<td align="char" char="/">301.1/151</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;80.95</td>
<td align="char" char=".">&#x2212;27.86</td>
<td rowspan="2" align="char" char=".">7.77</td>
</tr>
<tr>
<td align="char" char="/">301.1/179</td>
<td align="center">100</td>
<td align="char" char=".">&#x2212;75.02</td>
<td align="char" char=".">&#x2212;25.84</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Note: DP, declustering potential; CE, collision energy.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2-3-3">
<title>2.3.3 Preparation of Standard Working Solutions, Calibration Standards, Huashi Baidu Formula Extracts, and Plasma Samples</title>
<p>In this study, standard working solutions were made up of mixed standard and single standard. The single standard was made up of quercetin (100&#xa0;ng/ml). Piceatannol (5,000&#xa0;ng/ml), emodin (90&#xa0;ng/ml), rhein (15,000&#xa0;ng/ml), aloe-emodin (6,000&#xa0;ng/ml), physcion (150,000&#xa0;ng/ml), and luteolin (300&#xa0;ng/ml) were taken 10&#xa0;&#xb5;l each to form the mixed standard. Standard working solutions (100&#xa0;&#x3bc;l) were added to blank plasma (100&#xa0;&#x3bc;l) to form the calibration standards and stored at 4&#xb0;C until use.</p>
<p>HSBDF (1.23&#xa0;g/ml, 20&#xa0;ml) was filtered, concentrated, dried, and dissolved in 50&#xa0;ml water (containing 80% analytical-grade methanol) to collect HSBDF extracts (stored at 4&#xb0;C). Also, the HSBDF extracts were filtered through a 0.22-&#x3bc;m syringe filter when used.</p>
<p>In previous studies, rats fasted overnight with free access to water. The plasma samples (&#x223c;0.2&#xa0;ml) were collected into heparinized microcentrifuge tubes through the caudal vein at 2&#xa0;h after a single oral administration of HSBDF water decocted. The plasmas were centrifuged at 4,000&#xa0;rpm for 10&#xa0;min immediately after collection to obtain plasma. The plasma samples were stored at &#x2212;80&#xb0;C until analysis.</p>
<p>The calibration standards and plasma samples were treated with the protein precipitation method using methanol. The procedure was as follows: 100&#xa0;&#xb5;l samples were mixed with 800&#xa0;&#xb5;l methanol, then vortexed for 5&#xa0;min, and centrifuged at 13,000&#xa0;rpm for 10&#xa0;min. The supernatant was transferred into a clean tube and evaporated with a stream of nitrogen. The residue was dissolved with methanol and was filtered using a 0.22-&#x3bc;m syringe filter to test.</p>
</sec>
</sec>
<sec id="s2-4">
<title>2.4 Network Pharmacology Analysis</title>
<sec id="s2-4-1">
<title>2.4.1 PPI Analysis</title>
<p>The similarity ensemble approach (SEA) (<ext-link ext-link-type="uri" xlink:href="https://sea.bkslab.org/">https://sea.bkslab.org/</ext-link>) (<xref ref-type="bibr" rid="B19">Keiser et al., 2007</xref>) was used to predict targets of the key compounds in plasma (emodin, aloe-emodin, rhein, luteolin, and quercetin). The targets were imported into the STRING database (<ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>) (<xref ref-type="bibr" rid="B33">Szklarczyk et al., 2017</xref>), and the organism was set to &#x201c;Homo sapiens.&#x201d; The comprehensive score of protein interaction (confidence data &#x3e;0.9) was used to obtain the PPI information of the target. The major parameter &#x201c;degree&#x201d; was used to evaluate its topological features for each node in the interaction network. Based on the degree, bioinformatics (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.com.cn/">http://www.bioinformatics.com.cn/</ext-link>) was used to visualize the key targets (top 20 targets).</p>
</sec>
<sec id="s2-4-2">
<title>2.4.2 Enrichment</title>
<p>GO and KEGG enrichment was carried out using DAVID (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</ext-link>) databases. A total of 151 targets of key compounds in plasma were imported using the DAVID database. The select identifier was set to official gene, list type was set to gene list, species was set to &#x201c;Homo sapiens,&#x201d; and the threshold was set at <italic>p</italic> &#x3c; 0.05. Bioinformatics and GOChord of R language were used to construct the GO and pathway-target diagram, respectively.</p>
</sec>
</sec>
<sec id="s2-5">
<title>2.5 Test <italic>In Vitro</italic>
</title>
<sec id="s2-5-1">
<title>2.5.1 Cell Culture</title>
<p>A549 and MLE-12 cells were purchased from Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China) and maintained at 37&#xb0;C under 5% CO2 in DME/F-12 and 1,640 medium supplemented with 10% fetal bovine serum, respectively.</p>
<p>HSBDF condensed extract of 1.23&#xa0;g/ml was lyophilized using a freeze dryer (EYELA, Japan). Finally, 15.38&#xa0;g of lyophilized powder was obtained (yield, 11.23%). The dry powder was stored in an 80&#xb0;C refrigerator until use.</p>
</sec>
<sec id="s2-5-2">
<title>2.5.2 Cell Viability Analysis</title>
<p>Cell viability of A549 and MLE-12 cells were measured with the CCK-8 assay after compound intervention. The cells were seeded in 96-well plates at a density of 5 &#xd7; 10<sup>3</sup> cells/well in 200&#xa0;&#x3bc;l of culture media and grown for 4&#xa0;h. Second, they were treated with different concentrations of LPS, quercetin, luteolin, emodin, rhein, aloe-emodin, and HSBDF. Subsequently, 10&#xa0;&#x3bc;l of CCK-8 solution was added to each well, and the plates were incubated for 1&#xa0;h. The optical density of each well was determined at 450&#xa0;nm using a microplate reader (Bio-Rad, Hercules, CA, United States).</p>
</sec>
<sec id="s2-5-3">
<title>2.5.3 EdU Proliferation Analysis</title>
<p>EdU proliferation kit was employed for the determination of DNA synthetic capacity in proliferating cells. A549 cells were cultured in 96-well plates and grown for 4&#xa0;h. After being treated for 24&#xa0;h with compounds, the cells were strictly conducted following the instructions of the kit. Live cell imaging system (OLYMPUS, Japan, 20&#xd7;) and ImageJ software were employed for calculating the number of EdU-positive cells (green cells). The percentage of EdU-positive cells to total Hoechst 33342-positive cells (blue cells) was represented as the EdU-positive rate.</p>
</sec>
<sec id="s2-5-4">
<title>2.5.4 Enzyme-Linked Immunosorbent Assay, MDA, and T-SOD Analysis</title>
<p>The A549 cells culture medium was gathered and centrifuged (3,000&#xa0;r/min&#xd7;20&#xa0;min) at 4&#xb0;C. The supernatant liquid was taken out for detection of MDA, T-SOD, TNF-&#x3b1;, and IL-6. Enzyme-Linked Immunosorbent Assay (ELISA) (TNF-&#x3b1; and IL-6), MDA, and T-SOD steps were followed as per the instructions of the reagent kit.</p>
</sec>
<sec id="s2-5-5">
<title>2.5.5 Flow Cytometry Analysis</title>
<p>FITC-conjugated annexin V was used to detect apoptosis. A549 cells were cultured in six-well plates (1 &#xd7; 10<sup>5</sup> cells/well) for 4&#xa0;h before treatment. After adding LPS, quercetin, emodin, rhein, and HSBDF, the cells were incubated for 24&#xa0;h. Next, the cells were gathered and stained using the annexin V&#x2212;FITC/PI apoptosis detection kit following the manufacturer&#x2019;s instructions. The resulting fluorescence signal was detected by flow cytometry (BD, FACSCelesta).</p>
</sec>
<sec id="s2-5-6">
<title>2.5.6 Statistical Analysis</title>
<p>Analyses were performed using GraphPad Prism 6 software. The results are expressed as mean &#xb1; standard deviation (SD) of at least three independent experiments. The statistical differences between the two groups were compared by Student&#x2019;s t-test. <italic>p</italic> &#x3c; 0.05 was considered statistically significant.</p>
</sec>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>3 Results and Discussion</title>
<sec id="s3-1">
<title>3.1 Analysis of Key Anti-Inflammatory Compounds of Huashi Baidu Formula</title>
<sec id="s3-1-1">
<title>3.1.1 Huashi Baidu Formula Had Potential Effects to Inhibit Inflammation</title>
<p>To explore the anti-inflammatory effect of HSBDF, 1,613 compounds were docked with IL-6R and TNF-&#x3b1; by Schr&#x151;dinger. The compound with a docking score of &#x2264; &#x2212;5&#xa0;Kcal/mol was known as the potentially effective compound (<xref ref-type="bibr" rid="B17">Hsin et al., 2013</xref>). It can be seen that the total number of compounds with potential inhibitory activities was IL-6R (96) and TNF-&#x3b1; (111) as shown in <xref ref-type="table" rid="T2">Table 2</xref>, indicating that the formula had potential effects on inhibiting inflammation by acting on IL-6R and TNF-&#x3b1;.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Number statistics of molecular docking.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">No</th>
<th rowspan="2" align="center">Latin name of the herb</th>
<th rowspan="2" align="center">Chinese name of the herb</th>
<th colspan="2" align="center">Number of compounds with docking score &#x2264;&#x2212;5&#xa0;Kcal/mol</th>
</tr>
<tr>
<th align="center">IL-6R</th>
<th align="center">TNF-&#x3b1;</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">
<italic>E. sinica</italic>
</td>
<td align="left">Shengmahuang</td>
<td align="center">17</td>
<td align="center">25</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">
<italic>S. armeniacae amarum</italic>
</td>
<td align="left">Kuxingren</td>
<td align="center">2</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">
<italic>L. apetalum</italic>
</td>
<td align="left">Tinglizi</td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">
<italic>R. Paeoniae Rubra</italic>
</td>
<td align="left">Chishao</td>
<td align="center">9</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">
<italic>A. rugosus</italic>
</td>
<td align="left">Huoxiang</td>
<td align="center">5</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">
<italic>M. officinalis</italic>
</td>
<td align="left">Houpo</td>
<td align="center">1</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">
<italic>A. lancea</italic>
</td>
<td align="left">Cangzhu</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">
<italic>F. tsaoko</italic>
</td>
<td align="left">Caoguo</td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">
<italic>A. membranaceus</italic>
</td>
<td align="left">Shenghuangqi</td>
<td align="center">13</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">
<italic>G. uralensis</italic>
</td>
<td align="left">Gancao</td>
<td align="center">30</td>
<td align="center">41</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="left">Shengdahuang</td>
<td align="center">19</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">
<italic>P. cocos</italic>
</td>
<td align="left">Fuling</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">
<italic>R. Pinelliae Preparata</italic>
</td>
<td align="left">Fabanxia</td>
<td align="center">8</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">Total</td>
<td align="left"/>
<td align="left"/>
<td align="center">96</td>
<td align="center">111</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Note: The total number in the table is the result after weight removal.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In terms of a single herb, it was found that <italic>Glycyrrhiza uralensis</italic>, <italic>Ephedra sinica</italic>, and <italic>Rheum officinale</italic> were the top three docking herbs with two targets, respectively. Previous studies also demonstrated that Glycyrrhiza polysaccharide (50&#xa0;mg/kg) had a certain therapeutic effect on lung inflammation and oxidative damage in COPD mice (<xref ref-type="bibr" rid="B38">Wu et al., 2020</xref>); <italic>Ephedra sinica</italic> water plays an important role in distillates in arthritic rats (<xref ref-type="bibr" rid="B42">Yeom et al., 2006</xref>); <italic>Rheum officinale</italic> ethanol extract can effectively improve the pulmonary inflammation in mice infected with mycoplasma pneumonia (<xref ref-type="bibr" rid="B10">Gao et al., 2021</xref>). These results suggested that <italic>Glycyrrhiza uralensis</italic>, <italic>Ephedra sinica</italic>, and <italic>Rheum officinale</italic> were key herbs to inhibit inflammation, which was of great significance to ameliorate ALI.</p>
</sec>
<sec id="s3-1-2">
<title>3.1.2 Piceatannol, Emodin, Aloe-Emodin, Rhein, Physcion, Luteolin, and Quercetin Were Key Compounds</title>
<p>To determine anti-inflammatory key compounds, we selected the compounds, which conformed to Lipinski&#x2019;s rules (MW &#x3c; 500, H-bond donor&#x3c;5, H-bond acceptor&#x3c;10, log P (O/W) &#x3c; 5, and rotor &#x2264;10) and docking score &#x2264;&#x2212;5&#xa0;Kcal/mol, to analyze further. Based on the Pharmacopoeia of the People&#x2019;s Republic of China (2020) and the literature of every herb&#x2019;s main components, seven key compounds were selected from the top 50 compounds with high docking scores (<xref ref-type="table" rid="T3">Table 3</xref>). These compounds&#x2019; binding free energy was further calculated in Schr&#x151;dinger.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Information of the representative compounds.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Target</th>
<th align="center">Constituent</th>
<th align="left">Herb</th>
<th align="center">Docking score (Kcal/mol)</th>
<th align="center">Binding free energy (Kcal/mol)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="5" align="left">IL-6R</td>
<td align="left">Aloe-emodin</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.73</td>
<td align="char" char=".">&#x2212;38.50</td>
</tr>
<tr>
<td align="left">Physcion</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.43</td>
<td align="char" char=".">&#x2212;39.68</td>
</tr>
<tr>
<td align="left">Rhein</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.31</td>
<td align="char" char=".">&#x2212;23.75</td>
</tr>
<tr>
<td align="left">Luteolin</td>
<td align="left">
<italic>E. sinica</italic>
</td>
<td align="char" char=".">&#x2212;5.12</td>
<td align="char" char=".">&#x2212;36.29</td>
</tr>
<tr>
<td align="left">Quercetin</td>
<td align="left">
<italic>E. sinica</italic>, <italic>L. apetalum</italic>, <italic>A. rugosus</italic>, <italic>F. tsaoko</italic>, <italic>A. membranaceus</italic>, and <italic>G. uralensis</italic>
</td>
<td align="char" char=".">&#x2212;5.08</td>
<td align="char" char=".">&#x2212;39.35</td>
</tr>
<tr>
<td rowspan="6" align="left">TNF-&#x3b1;</td>
<td align="left">Aloe-emodin</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.57</td>
<td align="char" char=".">&#x2212;36.60</td>
</tr>
<tr>
<td align="left">
<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/667639">Piceatannol</ext-link>
</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.38</td>
<td align="char" char=".">&#x2212;37.68</td>
</tr>
<tr>
<td align="left">Emodin</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.36</td>
<td align="char" char=".">&#x2212;36.16</td>
</tr>
<tr>
<td align="left">Rhein</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.28</td>
<td align="char" char=".">&#x2212;29.87</td>
</tr>
<tr>
<td align="left">Physcion</td>
<td align="left">
<italic>R. officinale</italic>
</td>
<td align="char" char=".">&#x2212;5.28</td>
<td align="char" char=".">&#x2212;38.41</td>
</tr>
<tr>
<td align="left">Luteolin</td>
<td align="left">
<italic>E. sinica</italic>
</td>
<td align="char" char=".">&#x2212;5.24</td>
<td align="char" char=".">&#x2212;38.38</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The results indicated that piceatannol, emodin, aloe-emodin, rhein, physcion, luteolin, and quercetin had potential effects on inhibiting inflammation. Therefore, these compounds were considered key compounds to explore further. Also, we found that these compounds were mainly distributed in <italic>Glycyrrhiza uralensis</italic>, <italic>E. sinica</italic>, and <italic>R. officinale</italic>, which further provides support that <italic>Glycyrrhiza uralensis</italic>, <italic>E. sinica</italic>, and <italic>R. officinale</italic> were key herbs to treat ALI.</p>
</sec>
</sec>
<sec id="s3-2">
<title>3.2 Key Compounds in Plasma by LC/MS</title>
<p>In order to further analyze whether the seven key compounds (piceatannol, emodin, aloe-emodin, rhein, physcion, luteolin, and quercetin) were present in plasma, LC/MS was used. The results of preliminary experiments showed that the number of chromatographic peaks and intensity of peaks were the most strongly detected in 2&#xa0;h plasma after HSBDF administration. Therefore, 2&#xa0;h was selected to collect plasma after drug administration. Ion chromatograms of standards (S1) of key compounds, calibration standards (S2), HSBDF extracts (S3), and plasma sample (S4) are displayed in <xref ref-type="fig" rid="F1">Figure 1A</xref>. LC/MS analysis showed that a total of five compounds (emodin, aloe-emodin, rhein, luteolin, and quercetin) were identified in HSBDF extracts; four compounds (emodin, aloe-emodin, rhein, and luteolin) were identified in the plasma sample at 2&#xa0;h, considering that quercetin was rapidly hydrolyzed after oral administration (<xref ref-type="bibr" rid="B18">Jiang and Hu, 2012</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Key compounds analysis by LC/MS. <bold>(A)</bold> MRM chromatograms of key compounds (1&#x2013;7 represent piceatannol, emodin, aloe-emodin, rhein, physcion, luteolin, and quercetin, respectively); <bold>(B)</bold> structure of key compounds in plasma.</p>
</caption>
<graphic xlink:href="fphar-13-879268-g001.tif"/>
</fig>
<p>Therefore, LC/MS analysis showed that there were five key compounds in plasma of HSBDF, including emodin, aloe-emodin, rhein, luteolin, and quercetin. The structures of these compounds are shown in <xref ref-type="fig" rid="F1">Figure 1B</xref>.</p>
</sec>
<sec id="s3-3">
<title>3.3 Network Pharmacology of Key Compounds in Plasma</title>
<sec id="s3-3-1">
<title>3.3.1 PPI Analysis and Molecular Docking Verification</title>
<p>It was well known that network pharmacology contributes to exploring the potential mechanism of TCM in prevention and treatment of disease (<xref ref-type="bibr" rid="B21">Li et al., 2021</xref>). Therefore, in order to analyze the mechanism of key compounds in plasma, top 20 in 151 (confidence data &#x3e;0.9) targets of PPI are listed in <xref ref-type="fig" rid="F2">Figure 2A</xref>. The result showed that the top 20 targets of degree were TP53, SRC, PIK3R1, PIK3CA, AKT1, EGFR, CDK1, ESR1, PTPN11, CASP3, PTK2, FYN, MAPK8, LCK, CCNB1, CCNB2, AR, GSK3B, APP, and PTPN1.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Network pharmacology analysis of key compounds in plasma. <bold>(A)</bold> Top 20 targets of PPI; <bold>(B)</bold> molecular docking results of the key compounds in plasma with top five targets of PPI; <bold>(C)</bold> GO enrichment of the key compounds in plasma; <bold>(D)</bold> pathway-target diagram of key compounds in plasma.</p>
</caption>
<graphic xlink:href="fphar-13-879268-g002.tif"/>
</fig>
<p>In order to further validate the prediction of network pharmacology, five nodes, namely, TP53, SRC, PIK3R1, PIK3CA, and AKT1 with the highest degree were taken as examples to be analyzed. Their crystal structure was subjected and docked with corresponding compounds. Finally, constituent with docking score &#x2264; &#x2212;5 (Kcal/mol) was selected to analyze. The total proportion of TP53 (5/5), SRC (5/5), PIK3R1 (5/5), PIK3CA (5/5), and AKT1 (4/5) was 96%, and the results are shown in <xref ref-type="fig" rid="F2">Figure 2B</xref>. The results of molecular docking showed that the prediction accuracy was high, which verified the result of PPI.</p>
<p>It was reported that SRC could inhibit TLR4-induced inflammatory cytokines and promote anti-inflammatory cytokine IL-10, which plays an important role in the treatment of acute and chronic inflammation (<xref ref-type="bibr" rid="B20">Li et al., 2019</xref>). The pharmacological study suggested that <italic>G. baccata</italic> extract can upregulate <italic>AKT1</italic> gene expressions to protect the cells against oxidative damage and inflammation (<xref ref-type="bibr" rid="B27">Mart&#xed;nez et al., 2021</xref>). Moreover, the studies also suggested that TP53, PIK3R1, and PIK3CA were vital for inflammation (<xref ref-type="bibr" rid="B8">Eyileten et al., 2018</xref>; <xref ref-type="bibr" rid="B1">Busbee et al., 2021</xref>; <xref ref-type="bibr" rid="B28">Reske et al., 2021</xref>). Accordingly, the results indicate that emodin, aloe-emodin, rhein, luteolin, and quercetin may play an important role in inhibiting anti-inflammatory and anti-oxidative damage.</p>
</sec>
<sec id="s3-3-2">
<title>3.3.2 GO and KEGG Enrichment Analysis</title>
<p>To explore the regulatory mechanisms of key compounds in plasma, a total of 267 terms were enriched (<italic>p</italic> &#x3c; 0.01), and the top five of GO enrichment were visualized, as shown in <xref ref-type="fig" rid="F2">Figure 2C</xref>. Among which, biological processes (BP) include protein phosphorylation, peptidyl-serine phosphorylation, and protein autophosphorylation, etc; cell composition (CC) includes cytosol, plasma membrane, extracellular exosome, cytoplasm, and nucleoplasm; and molecular function (MF) includes protein kinase activity, protein serine/threonine kinase activity, ATP binding, and so on.</p>
<p>Moreover, we had used 151 targets to enrich 107 pathways (<italic>p</italic> &#x3c; 0.05), and the top 20 targets and top 20 pathways are shown in <xref ref-type="fig" rid="F2">Figure 2D</xref>. It can be seen that the HIF-1 signaling pathway, the ErbB signaling pathway, the TNF signaling pathway, and so on may be the key regulated pathways of emodin, aloe-emodin, rhein, luteolin, and quercetin. Also, studies have shown that the HIF-1&#x3b1; signaling pathway was related to inflammation, and arginine can regulate HIF-1&#x3b1; to suppress the inflammatory response (<xref ref-type="bibr" rid="B2">Chen et al., 2020</xref>). The Er7bB signaling pathway was associated with oxidative stress, and it was reported that the ErbB4 system of the heart was activated at early stages of chronic heart failure to enhance the cardiomyocyte resistance to oxidative stress (<xref ref-type="bibr" rid="B30">Shchendrigina et al., 2020</xref>). The TNF signaling pathways and inflammatory pathways can suppress inflammation (<xref ref-type="bibr" rid="B22">Liang et al., 2021</xref>).</p>
<p>Network pharmacology results suggested that emodin, aloe-emodin, rhein, luteolin, and quercetin likely treated ALI by regulating the biological function and pathways related to anti-inflammatory and anti-oxidative damage.</p>
</sec>
</sec>
<sec id="s3-4">
<title>3.4 Test <italic>In Vitro</italic> of Key Compounds in Plasma</title>
<sec id="s3-4-1">
<title>3.4.1 Inflammatory Model With LPS</title>
<p>A549 is a human alveolar epithelial cell line. It is often used to research lung diseases, such as ARDS (<xref ref-type="bibr" rid="B24">Lin et al., 2020</xref>), ALI (<xref ref-type="bibr" rid="B11">Geiser et al., 2001</xref>; <xref ref-type="bibr" rid="B45">Zhao et al., 2021</xref>). Therefore, we used A549 to further study ALI. To determine the optimal concentration and time of LPS, cell counting kit-8 (CCK-8) was used to detect the viability of A549 cells in this study. As shown in <xref ref-type="fig" rid="F3">Figure 3</xref>, LPS markedly decreased the cell viability of A549 cells in a dose- and time-dependent manner. The cell viability was reduced by approximately 50% when A549 was subjected to 6.25&#xa0;&#x3bc;g/ml of LPS compared with blank (<italic>p</italic> &#x3c; 0.01) in 24&#xa0;h, indicating that 6.25&#xa0;&#x3bc;g/ml of LPS is deleterious to the epithelial cell. LPS of 12.5, 25, 50, or 100&#xa0;&#x3bc;g/ml decreased cell viability more prominently than 6.25&#xa0;&#x3bc;g/ml LPS did, which demonstrated that LPS induced cell viability loss in a dose-dependent manner and that the lowest effective injury dose of 24&#xa0;h LPS treatment was 6.25&#xa0;&#x3bc;g/ml (<xref ref-type="bibr" rid="B25">Liu et al., 2021</xref>). Consequently, further experiments were performed with 6.25&#xa0;&#x3bc;g/ml of LPS at 24&#xa0;h.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Cell Viability after different treatments of LPS (&#x2a;<italic>p</italic> &#x3c; 0.05, <sup>&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 versus blank).</p>
</caption>
<graphic xlink:href="fphar-13-879268-g003.tif"/>
</fig>
</sec>
<sec id="s3-4-2">
<title>3.4.2 Cell Viability of the Huashi Baidu Formula and Key Compounds in Plasma</title>
<p>In order to determine the effect of HSBDF and key compounds in plasma on the viability of A549 cells, CCK-8 was used to detect the viability of cells treated with different concentrations of drug for 24&#xa0;h (<xref ref-type="fig" rid="F4">Figure 4</xref>). The results showed that HSBDF and key compounds in plasma can increase the cytotoxicity of A549 cells in a dose-dependent manner. Moreover, we found that A549 cell proliferation was markedly promoted with low concentration of quercetin (1.5625&#xa0;&#x3bc;M), emodin (3.125&#xa0;&#x3bc;M), rhein (1.5625&#xa0;&#x3bc;M), and HSBDF (0.03125&#xa0;mg/ml), whereas aloe-emodin and luteolin did not. The cell viability was further tested for normal epithelial cells (MLE12) after treating with low concentration of quercetin, emodin, and rhein. (<xref ref-type="sec" rid="s12">Supplementary Figure S1</xref>). We found that the viability of lung epithelial cells, such as A549 and MLE-12, can be increased by these key compounds.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Cell viability after treatments of HSBDF and key compounds in plasma. (cell viability was detected by CCK-8; &#x2a;<italic>p</italic> &#x3c; 0.05, <sup>&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 versus blank).</p>
</caption>
<graphic xlink:href="fphar-13-879268-g004.tif"/>
</fig>
</sec>
<sec id="s3-4-3">
<title>3.4.3 Huashi Baidu Formula and Active Compounds Promote A549 Cell Proliferation in an Inflammatory Environment</title>
<p>To further evaluate the effects of HSBDF, quercetin, emodin, and rhein on A549 cells grown in an inflammatory environment, the EdU proliferation kit and cck-8 were used to detect proliferating cells and the viability of cells, respectively. As shown in <xref ref-type="fig" rid="F5">Figure 5A</xref>, we found that inflammation stimulated by LPS inhibited the proliferation of A549 cells, whereas inhibition of proliferation was decreased by quercetin (1.5625&#xa0;&#x3bc;M), emodin (3.125&#xa0;&#x3bc;M), rhein (1.5625&#xa0;&#x3bc;M), and HSBDF (0.03125&#xa0;mg/ml). The stimulative proliferation of quercetin (1.5625&#xa0;&#x3bc;M), emodin (3.125&#xa0;&#x3bc;M), rhein (1.5625&#xa0;&#x3bc;M), and HSBDF (0.03125&#xa0;mg/ml) on A549 cells cultured in an inflammatory environment was also confirmed by EdU proliferation staining (<xref ref-type="fig" rid="F5">Figures 5B1,B2</xref>). These results demonstrate that quercetin, emodin, rhein, and HSBDF were effective in inhibiting inflammation. Therefore, HSBDF (0.03125&#xa0;mg/ml), quercetin (1.5625&#xa0;&#x3bc;M), emodin (3.125&#xa0;&#x3bc;M), and rhein (1.5625&#xa0;&#x3bc;M) were active compounds for further experiments.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effect of HSBDF and active compounds treatment on cell proliferation in LPS-stimulated A549 cells. <bold>(A)</bold> Cell proliferation test by CCK-8; <bold>(B1,B2)</bold> DNA synthesis activity in cells examined by EdU staining (magnification, x20) (&#x2a;<italic>p</italic> &#x3c; 0.05, <sup>&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 versus blank; &#x25b3;<italic>p</italic> &#x3c; 0.05, &#x25b3;&#x25b3;<italic>p</italic> &#x3c; 0.01 versus LPS).</p>
</caption>
<graphic xlink:href="fphar-13-879268-g005.tif"/>
</fig>
</sec>
<sec id="s3-4-4">
<title>3.4.4 Huashi Baidu Formula and Active Compounds Decrease Expression of TNF-&#x3b1; and IL-6, Decrease Expression of MDA, and Increase Expression of T-SOD in A549 Cells in an Inflammatory Environment</title>
<p>To determine the effect of HSBDF and active compounds on the expression of inflammatory cytokine, ELISA was used to measure the expression levels of IL-6 and TNF-&#x3b1; in the cell supernatant liquid. The elevated expressions of TNF-&#x3b1; and IL-6 induced by LPS in A549 cells were inhibited by quercetin (1.5625&#xa0;&#x3bc;M), emodin (3.125&#xa0;&#x3bc;M), rhein (1.5625&#xa0;&#x3bc;M), and HSBDF (0.03125&#xa0;mg/ml) (<xref ref-type="fig" rid="F6">Figure 6A</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>
<bold>(A)</bold> Effects of HSBDF and active compound treatment on the expression levels of inflammatory cytokine (IL-6 and TNF-&#x3b1;) in LPS-stimulated A549 cells by the ELISA test. <bold>(B)</bold> Effects of HSBDF and active compound treatment on oxidative stress (MDA and T-SOD) in LPS-stimulated A549 cells (&#x2a;<italic>p</italic> &#x3c; 0.05, <sup>&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 versus blank; <sup>&#x25b3;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x25b3;&#x25b3;</sup>
<italic>p</italic> &#x3c; 0.01 versus LPS).</p>
</caption>
<graphic xlink:href="fphar-13-879268-g006.tif"/>
</fig>
<p>Simultaneously, the anti-oxidative stress of HSBDF and active compounds was further researched in an inflammatory environment. We found that the oxidative stress injury was weakened after treatment of HSBDF and active compounds. The SOD was enhanced significantly by active compounds, while the MDA was decreased (<xref ref-type="fig" rid="F6">Figure 6B</xref>).</p>
<p>These results further verify that network pharmacology results indicate that emodin, rhein, and quercetin have the function of anti-inflammation and act against oxidative damage.</p>
</sec>
<sec id="s3-4-5">
<title>3.4.5 Huashi Baidu Formula and Active Compounds Inhibit A549 Cell Apoptosis in an Inflammatory Environment</title>
<p>LPS has been known to cause alveolar epithelial cell apoptosis that characterizes ALI (<xref ref-type="bibr" rid="B16">Hou et al., 2021</xref>). Therefore, the anti-apoptosis of HSBDF and active compounds was further investigated in an inflammatory environment. We investigated the effects of drugs on the apoptosis of A549 cells in an inflammatory environment by flow cytometry. We found that LPS increased A549 cell apoptosis. The apoptosis was significantly decreased after the intervention of quercetin, emodin, rhein, and HSBDF in an inflammatory environment (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Effects of HSBDF and active compound treatment on apoptosis in LPS-stimulated A549 cells (&#x2a;<italic>p</italic> &#x3c; 0.05, <sup>&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 versus blank; <sup>&#x25b3;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x25b3;&#x25b3;</sup>
<italic>p</italic> &#x3c; 0.01 versus LPS).</p>
</caption>
<graphic xlink:href="fphar-13-879268-g007.tif"/>
</fig>
</sec>
</sec>
</sec>
<sec id="s4">
<title>4 Molecular Dynamic Simulation and Binding Interaction Pattern of the Complex of Active Compounds and Protein</title>
<p>To further confirm the molecular docking insights and analyze the conformation stability of active compounds and target proteins, molecular dynamic simulations were conducted for rhein and quercetin with IL-6R and rhein and emodin with the TNF-&#x3b1; complex in 50&#xa0;ns by the Desmond module. The root mean square deviation (RMSD) plot in <xref ref-type="fig" rid="F8">Figure 8A</xref> showed that the fluctuation values of RMSD of both systems were stable within a certain range by simulating 50&#xa0;ns, which reveals that the simulation was well equilibrated during 50&#xa0;ns and the ligand did not undergo a remarkable conformational change.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Molecular dynamics simulation study. <bold>(A)</bold> RMSD of the active compound&#x2013;protein complex in 50 ns, which is made up of a number of &#x3b1;-carbon (C&#x3b1;) atoms, throughout the simulations; <bold>(B,C)</bold> Binding interaction patterns of rhein and quercetin with IL-6R; <bold>(D,E)</bold> Binding interaction patterns of rhein and emodin with TNF-&#x3b1;.</p>
</caption>
<graphic xlink:href="fphar-13-879268-g008.tif"/>
</fig>
<p>The interactions of active compounds and target proteins were further elaborated based on the hydrogen bonds, hydrophobic, ionic, and water bridges during 50-ns simulation. As shown in <xref ref-type="fig" rid="F8">Figure 8A</xref> and <xref ref-type="sec" rid="s12">Supplementary Figure S2</xref>, the interaction between rhein and IL-6R&#x2019;s residues (<xref ref-type="fig" rid="F8">Figure 8B</xref>), such as GLU277, PHE279, GLN281, ARG233, ARG231, GLU163, and TYR230, was a stable key, for example, the H-bond and hydrophobic interaction between rhein and GLU277 and PHE29, respectively (<xref ref-type="fig" rid="F8">Figure 8C</xref>). The interaction between quercetin and IL-6R&#x2019;s residues, such as ARG233, PHE234, VAL251, LYS252, ASP253, GLU278, PHE279, and GLU163, was a stable key, for example, the hydrophobic interaction betweenARG233 and quercetin. TYR59, TYR151, HIS15, GLY149, TYR119, GLN61, ILE154, and SER60 were key interacting residues of TNF-&#x3b1;, among which, TYR59 and TYR151 formed a stable hydrophobic and H-bond interaction with rhein, respectively (<xref ref-type="fig" rid="F8">Figure 8D</xref>). TYR59, GLN125, TYR151, LEU157, LEU55, LEU57, and SER60 were key interacting residues of TNF-&#x3b1;, which mainly formed H-bond and hydrophobic and ionic interaction with emodin (<xref ref-type="fig" rid="F8">Figure 8E</xref>).</p>
<p>These results suggested that binding of ligand molecules (rhein, quercetin, and emodin) stabilizes the protein structure without noticeable structural changes in native conformation. That is the conformation of the complex was stable, and the residues are derived from stable complexes.</p>
</sec>
<sec id="s5">
<title>5 Pharmacokinetic Properties of Active Compounds</title>
<p>The ADMET property prediction is fundamental for the selection of the most promising compounds for further development. The active compounds (quercetin, emodin, and rhein) were subjected to predictions of pharmacokinetic properties using ProTox-II and QikProp. As shown in <xref ref-type="table" rid="T4">Table 4</xref>, active compounds conformed to RO5 and QPlogBB, and CNS showed that a low risk of central nervous system damage. The QPlogHERG of emodin and rhein was within the specified range, indicating that the risk of cardiotoxicity of emodin and rhein was low. The toxicity level of emodin and rhein of Class V was relatively safe; the LD50 of quercetin was 159&#xa0;mg/kg and belonged to Class III, indicating quercetin has potential safety risks. These suggested that emodin and rhein were the most promising compounds.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Pharmacokinetic properties of the key compounds.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound</th>
<th align="center">RO5<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</th>
<th align="center">%HOA<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>
</th>
<th align="center">CNS<xref ref-type="table-fn" rid="Tfn3">
<sup>c</sup>
</xref>
</th>
<th align="center">QPlogBB<xref ref-type="table-fn" rid="Tfn4">
<sup>d</sup>
</xref>
</th>
<th align="center">QPlogHERG<xref ref-type="table-fn" rid="Tfn5">
<sup>e</sup>
</xref>
</th>
<th align="center">LD50 (mg/kg)</th>
<th align="center">Toxicity class<xref ref-type="table-fn" rid="Tfn6">
<sup>f</sup>
</xref>
</th>
<th align="center">Hepatotoxicity</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Emodin</td>
<td align="center">0</td>
<td align="char" char=".">68.29</td>
<td align="center">&#x2212;2</td>
<td align="char" char=".">&#x2212;1.53</td>
<td align="char" char=".">&#x2212;4.32</td>
<td align="center">5,000</td>
<td align="center">V</td>
<td align="center">Inactive</td>
</tr>
<tr>
<td align="left">Rhein</td>
<td align="center">0</td>
<td align="char" char=".">47.47</td>
<td align="center">&#x2212;2</td>
<td align="char" char=".">&#x2212;1.97</td>
<td align="char" char=".">&#x2212;2.70</td>
<td align="center">5,000</td>
<td align="center">V</td>
<td align="center">Inactive</td>
</tr>
<tr>
<td align="left">Quercetin</td>
<td align="center">0</td>
<td align="char" char=".">52.20</td>
<td align="center">&#x2212;2</td>
<td align="char" char=".">&#x2212;2.40</td>
<td align="char" char=".">&#x2212;5.13</td>
<td align="center">159</td>
<td align="center">III</td>
<td align="center">Inactive</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>a</label>
<p>Note: acceptable range: Max.4.</p>
</fn>
<fn id="Tfn2">
<label>b</label>
<p>acceptable range: 0&#x2013;100.</p>
</fn>
<fn id="Tfn3">
<label>c</label>
<p>acceptable range: &#x2212;2 (inactive) &#x2b;2 (active).</p>
</fn>
<fn id="Tfn4">
<label>d</label>
<p>acceptable range: &#x2212;3.0 to 1.2.</p>
</fn>
<fn id="Tfn5">
<label>e</label>
<p>acceptable range: &#x3c;&#x2212;5.</p>
</fn>
<fn id="Tfn6">
<label>f</label>
<p>[Class I: death after swallowing (LD50 &#x2264; 5); Class II: death after swallowing (5 &#x3c; LD50 &#x2264; 50); Class III: toxic after swallowing (50 &#x3c; LD50 &#x2264; 300); Class IV: harmful after swallowing (300 &#x3c; LD50 &#x2264; 2000); Class V: may be harmful after swallowing (2000 &#x3c; LD50 &#x2264; 5,000); Class VI: non-toxic (LD50 &#x3e; 5,000)].</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s6">
<title>6 Conclusion</title>
<p>Based on TCM theory and documentation, HSBDF including two classical prescriptions of MXSGD (<italic>E. sinica</italic>, <italic>S. armeniacae amarum</italic>, and <italic>Glycyrrhiza uralensis</italic>) and HXZQP (<italic>A. rugosus</italic>, <italic>M. officinalis</italic>, <italic>R. Pinelliae Preparata</italic>, <italic>A. lancea</italic>, <italic>P. cocos</italic>, and <italic>Glycyrrhiza uralensis</italic>) was recommended to treat ALI at the later stages of COVID-19 by the NHC. Molecular docking results showed that the total number of compounds with potential inhibitory activities of MXSGD (120) against IL-6R and TNF-&#x3b1; was higher than that of HXZQP (110). The results indicated that MXSGD was more outstanding in anti-inflammation than HXZQP, which up to the TCM theory that MXSGD can regulate lung mechanisms such as diffuse the lung qi. Also, previous studies confirmed that MXSGD played a role in suppressing cytokine storm and immune regulation and protecting the pulmonary alveolar&#x2013;capillary barrier (<xref ref-type="bibr" rid="B35">Wang et al., 2020</xref>).</p>
<p>In terms of single herb, we found that <italic>Glycyrrhiza uralensis</italic>, <italic>E. sinica</italic>, and <italic>R. officinale</italic> were key herbs with the potential to inhibit inflammation, which was of great significance to ameliorate ALI. These results are in accordance with the Chinese medicine theory that <italic>Glycyrrhiza uralensis</italic> and <italic>E. sinica</italic> belong to the lung channel; <italic>R. officinale</italic> belongs to the interior&#x2013;exterior of the large intestine channel and the lung. Therefore, <italic>Glycyrrhiza uralensis</italic>, <italic>E. sinica</italic>, and <italic>R. officinale</italic> had properties to treat lung-related diseases. These results were a significant guide for the compatibility of TCM in the treatment of ALI.</p>
<p>Quercetin was outstanding in inhibiting anti-inflammation and anti-oxidative stress in this study. Considering that quercetin has potential safety risks, the structural optimization of quercetin to avoid toxicity but retain anti-inflammatory and anti-oxidant features is worth further study.</p>
<p>In summary, this study made good use of chemical bioinformatics analysis, including molecular docking, LC/MS, network pharmacology, test <italic>in vitro</italic>, molecular dynamic simulation, binding interaction pattern analysis, and pharmacokinetic properties to systematically study the regulatory mechanisms of HSBDF and its active compounds in plasma in treating ALI. Overwhelming lung inflammation, oxidative stress, and cell apoptosis were involved in the whole pathological process of ALI. Our results suggested that HSBDF and its active components in plasma (quercetin, emodin, and rhein) have significant effects on anti-inflammation, anti-oxidative stress, and decreasing cell apoptosis in treating ALI. Moreover, quercetin, emodin, and rhein, key active components in plasma, had a stable affinity with IL-6R and TNF-&#x3b1;, which are worthy of further development and utilization for ALI.</p>
</sec>
</body>
<back>
<sec id="s7">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s12">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s8">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Committee for Ethics in the Laboratory Animal Center of Gansu University of Chinese Medicine (number: 2021-182).</p>
</sec>
<sec id="s9">
<title>Author Contributions</title>
<p>YrW, XJ, QqW, and YL conceived and designed the study. QF, YfW, and QfW provided the guidance of LC/MS. YrW operated the LC/MS experiment with the assistance of YL, XzL, JwL, and SyW. YrW collected the compounds of HSBDF and targets and performed the cell experiment. YrW, XJ, and YW performed the network pharmacology analysis. MZ, JL, CxL, ChL, and LL performed molecular dynamic simulation, YrW and XJ performed molecular docking and wrote the manuscript. All authors were responsible for reviewing data. All authors have read and approved the final manuscript.</p>
</sec>
<sec id="s10">
<title>Funding</title>
<p>This study was supported by the Special Project of COVID-19 Emergent TCM Treatment of National Administration of Traditional Chinese Medicine (No. 2021ZYLCYJ08-3), Provincial University Industry Support Project in Gansu (2020C-36), and National Natural Science Foundation of China (No. NSFC 82004202).</p>
</sec>
<sec sec-type="COI-statement" id="s11">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s13">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.879268/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2022.879268/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material>
<label>Supplementary Figure S1</label>
<caption>
<p>Cell viability for MLE12 after treatments of HSBDF and key compounds in plasma (cell viability was detected by CCK-8,&#x2a;<italic>P</italic> &#x3c; 0.05 versus blank).</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S2</label>
<caption>
<p>Histogram and percentage graph of protein&#x2013;active compound interaction in molecular dynamics simulation. <bold>(B,C)</bold> Protein&#x2013;ligand interaction of rhein and quercetin with IL-6R; <bold>(C,D)</bold> protein&#x2013;ligand interaction of rhein and emodin with TNF-&#x3b1;.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image2.TIF" id="SM1" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.TIF" id="SM2" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Busbee</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Bam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Abdulla</surname>
<given-names>O. A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>J. P. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Dysregulated TP53 Among PTSD Patients Leads to Downregulation of miRNA Let-7a and Promotes an Inflammatory Th17 Phenotype</article-title>. <source>Front. Immunol.</source> <volume>12</volume>, <fpage>815840</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.815840</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>M. X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Arginine Is Neuroprotective through Suppressing HIF-1&#x3b1;/LDHA-Mediated Inflammatory Response after Cerebral Ischemia/reperfusion Injury</article-title>. <source>Mol. Brain</source> <volume>13</volume> (<issue>1</issue>), <fpage>63</fpage>. <pub-id pub-id-type="doi">10.1186/s13041-020-00601-9</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>Gasotransmitter CO Attenuates Bleomycin-Induced Fibroblast Senescence via Induction of Stress Granule Formation</article-title>. <source>Oxid. Med. Cel Longev.</source> <volume>2021</volume>, <fpage>9926284</fpage>. <pub-id pub-id-type="doi">10.1155/2021/9926284</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Targeting Protein Arginine Methyltransferase 5 in Cancers: Roles, Inhibitors and Mechanisms</article-title>. <source>Biomed. Pharmacother.</source> <volume>144</volume>, <fpage>112252</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112252</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021c</year>). <article-title>Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases</article-title>. <source>Oxid. Med. Cel Longev.</source> <volume>2021</volume>, <fpage>3206982</fpage>. <pub-id pub-id-type="doi">10.1155/2021/3206982</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>S. T. M.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brooun</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Deal</surname>
<given-names>J. G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Structure-Based Drug Design and Synthesis of PI3K&#x3b1;-Selective Inhibitor (PF-06843195)</article-title>. <source>J. Med. Chem.</source> <volume>64</volume> (<issue>1</issue>), <fpage>644</fpage>&#x2013;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01652</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X. G.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation</article-title>. <source>PloS one</source> <volume>9</volume> (<issue>9</issue>), <fpage>e106225</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0106225</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyileten</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wicik</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mirowska-Guzel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Soplinska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Indolfi</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke-A Comprehensive Review and Bioinformatic Analysis</article-title>. <source>Cells</source> <volume>7</volume> (<issue>12</issue>), <fpage>249</fpage>. <pub-id pub-id-type="doi">10.3390/cells7120249</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Characteristic Anti-inflammatory and Antioxidative Effects of Enzymatic- and Acidic- Hydrolysed Mycelium Polysaccharides by Oudemansiella Radicata on LPS-Induced Lung Injury</article-title>. <source>Carbohydr. Polym.</source> <volume>204</volume>, <fpage>142</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2018.09.073</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y. D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Effects of Different Extraction Processed Rhei Radix et Rhizoma on Pulmonary Inflammation in Mice Infected with Mycoplasma Pneumoniae</article-title>. <source>Chin. J. Mod. Applied Pharmacy</source> <volume>38</volume> (<issue>22</issue>), <fpage>2781</fpage>&#x2013;<lpage>2786</lpage>. <comment>(in Chinese)</comment>. <pub-id pub-id-type="doi">10.13748/j.cnki.issn1007-7693.2021.22.003</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geiser</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Atabai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jarreau</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Ware</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Pugin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Matthay</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Pulmonary Edema Fluid from Patients with Acute Lung Injury Augments <italic>In Vitro</italic> Alveolar Epithelial Repair by an IL-1beta-dependent Mechanism</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>163</volume> (<issue>6</issue>), <fpage>1384</fpage>&#x2013;<lpage>1388</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm.163.6.2006131</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gollner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arnhof</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Boehmelt</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Discovery of Novel Spiro[3H-indole-3,2&#x27;-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-P53 Interaction</article-title>. <source>J. Med. Chem.</source> <volume>59</volume> (<issue>22</issue>), <fpage>10147</fpage>&#x2013;<lpage>10162</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00900</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Oslob</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Braisted</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Whitty</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Small-molecule Inhibition of TNF-Alpha</article-title>. <source>Science</source> <volume>310</volume> (<issue>5750</issue>), <fpage>1022</fpage>&#x2013;<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1126/science.1116304</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sandstrom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chorny</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Harries</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>R. A.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Crystal Structure of Human Aquaporin 4 at 1.8 A and its Mechanism of Conductance</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>106</volume> (<issue>18</issue>), <fpage>7437</fpage>&#x2013;<lpage>7442</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0902725106</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations</article-title>. <source>J. Chem. Inf. Model.</source> <volume>51</volume> (<issue>1</issue>), <fpage>69</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1021/ci100275a</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>MitoQ Alleviates LPS-Mediated Acute Lung Injury through Regulating Nrf2/Drp1 Pathway</article-title>. <source>Free Radic. Biol. Med.</source> <volume>165</volume>, <fpage>219</fpage>&#x2013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.01.045</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsin</surname>
<given-names>K. Y.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kitano</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Combining Machine Learning Systems and Multiple Docking Simulation Packages to Improve Docking Prediction Reliability for Network Pharmacology</article-title>. <source>PLoS One</source> <volume>8</volume> (<issue>12</issue>), <fpage>e83922</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0083922</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Mutual Interactions between Flavonoids and Enzymatic and Transporter Elements Responsible for Flavonoid Disposition via Phase II Metabolic Pathways</article-title>. <source>RSC Adv.</source> <volume>2</volume> (<issue>21</issue>), <fpage>7948</fpage>&#x2013;<lpage>7963</lpage>. <pub-id pub-id-type="doi">10.1039/C2RA01369J</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keiser</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Armbruster</surname>
<given-names>B. N.</given-names>
</name>
<name>
<surname>Ernsberger</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Shoichet</surname>
<given-names>B. K.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Relating Protein Pharmacology by Ligand Chemistry</article-title>. <source>Nat. Biotechnol.</source> <volume>25</volume> (<issue>2</issue>), <fpage>197</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1284</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Siglec-G Deficiency Ameliorates Hyper-Inflammation and Immune Collapse in Sepsis via Regulating Src Activation</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>2575</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02575</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Systematic Insight into the Active Constituents and Mechanism of Guiqi Baizhu for the Treatment of Gastric Cancer</article-title>. <source>Cancer Sci.</source> <volume>112</volume> (<issue>5</issue>), <fpage>1772</fpage>&#x2013;<lpage>1784</lpage>. <pub-id pub-id-type="doi">10.1111/cas.14851</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Natural Compound Puerarin Alleviates Inflammation and Apoptosis in Experimental Cell and Rat Preeclampsia Models</article-title>. <source>Int. Immunopharmacol.</source> <volume>99</volume>, <fpage>108001</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2021.108001</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W. I.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>Gloor</surname>
<given-names>S. L.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>An ATP-Site On-Off Switch that Restricts Phosphatase Accessibility of Akt</article-title>. <source>Sci. Signal.</source> <volume>5</volume> (<issue>223</issue>), <fpage>ra37</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2002618</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The rCC16 Protein Protects against LPS-Induced Cell Apoptosis and Inflammatory Responses in Human Lung Pneumocytes</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>1060</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.01060</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>BMSC-derived Exosomes Ameliorate LPS-Induced Acute Lung Injury by miR-384-5p-Controlled Alveolar Macrophage Autophagy</article-title>. <source>Oxid. Med. Cel Longev.</source> <volume>2021</volume>, <fpage>9973457</fpage>. <pub-id pub-id-type="doi">10.1155/2021/9973457</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manchester</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Walkup</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rivin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Evaluation of pKa Estimation Methods on 211 Druglike Compounds</article-title>. <source>J. Chem. Inf. Model.</source> <volume>50</volume> (<issue>4</issue>), <fpage>565</fpage>&#x2013;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1021/ci100019p</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;nez</surname>
<given-names>M.-A.</given-names>
</name>
<name>
<surname>Ares</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mart&#xed;nez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lopez-Torres</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Maximiliano</surname>
<given-names>J.-E.</given-names>
</name>
<name>
<surname>Rodr&#xed;guez</surname>
<given-names>J.-L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Brown marine Algae Gongolaria Baccata Extract Protects Caco-2 Cells from Oxidative Stress Induced by Tert-Butyl Hydroperoxide</article-title>. <source>Food Chem. Toxicol.</source> <volume>156</volume>, <fpage>112460</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2021.112460</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reske</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Holladay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siwicki</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Skalski</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Harkins</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Co-existing TP53 and ARID1A Mutations Promote Aggressive Endometrial Tumorigenesis</article-title>. <source>Plos Genet.</source> <volume>17</volume> (<issue>12</issue>), <fpage>e1009986</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1009986</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>TCMSP: a Database of Systems Pharmacology for Drug Discovery from Herbal Medicines</article-title>. <source>J. Cheminform.</source> <volume>6</volume>, <fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2946-6-13</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shchendrigina</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Zhbanov</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Privalova</surname>
<given-names>E. V.</given-names>
</name>
<name>
<surname>Iusupova</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Bytdaeva</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Danilogorskaya</surname>
<given-names>Y. A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection</article-title>. <source>Kardiologiia</source> <volume>60</volume> (<issue>11</issue>), <fpage>1222</fpage>. <pub-id pub-id-type="doi">10.18087/cardio.2020.11.n1222</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheikh</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Jiffri</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Ashraf</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Kamal</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Beg</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Structural Studies on Inhibitory Mechanisms of Antibiotic, Corticosteroid and Catecholamine Molecules on Lactoperoxidase</article-title>. <source>Life Sci.</source> <volume>207</volume>, <fpage>412</fpage>&#x2013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2018.06.027</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Icariin Reduces LPS-Induced Acute Lung Injury in Mice Undergoing Bilateral Adrenalectomy by Regulating GR&#x3b1;</article-title>. <source>Eur. J. Pharmacol.</source> <volume>876</volume>, <fpage>173032</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173032</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wyder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Simonovic</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>The STRING Database in 2017: Quality-Controlled Protein-Protein Association Networks, Made Broadly Accessible</article-title>. <source>Nucleic Acids Res.</source> <volume>45</volume> (<issue>D1</issue>), <fpage>D362</fpage>&#x2013;<lpage>D368</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw937</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Traditional Chinese Medicine to Treat COVID-19: the Importance of Evidence-Based Research</article-title>. <source>Drug Discov. Ther.</source> <volume>14</volume> (<issue>3</issue>), <fpage>149</fpage>&#x2013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.5582/ddt.2020.03054</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Ru</surname>
<given-names>Y. H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Utilizing Integrating Network Pharmacological Approaches to Investigate the Potential Mechanism of Ma Xing Shi Gan Decoction in Treating COVID-19</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>24</volume> (<issue>6</issue>), <fpage>3360</fpage>&#x2013;<lpage>3384</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_202003_20704</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>E. L. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Selectively Targeting Individual Bromodomain: Drug Discovery and Molecular Mechanisms</article-title>. <source>Pharmacol. Res.</source> <volume>172</volume>, <fpage>105804</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2021.105804</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>In Silico predication of Nuclear Hormone Receptors for Organic Pollutants by Homology Modeling and Molecular Docking</article-title>. <source>Toxicol. Lett.</source> <volume>191</volume> (<issue>1</issue>), <fpage>69</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2009.08.005</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>X. F.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G. L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Effects of Glycyrrhiza Polysaccharide on Inflammation and Oxidative Damage of Lung Tissue in Mice</article-title>. <source>J. Gansu Agric. Univ.</source> <volume>55</volume> (<issue>05</issue>), <fpage>8</fpage>&#x2013;<lpage>14&#x2b;30</lpage>. <comment>(in Chinese)</comment>. <pub-id pub-id-type="doi">10.13432/j.cnki.jgsau.2020.05.002</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Busino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hinds</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Marionni</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Saifee</surname>
<given-names>N. H.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>M. F.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>SCF(FBXL3) Ubiquitin Ligase Targets Cryptochromes at Their Cofactor Pocket</article-title>. <source>Nature</source> <volume>496</volume> (<issue>7443</issue>), <fpage>64</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1038/nature11964</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>TCMID: Traditional Chinese Medicine Integrative Database for Herb Molecular Mechanism Analysis</article-title>. <source>Nucleic Acids Res.</source> <volume>41</volume> (<issue>Database issue</issue>), <fpage>D1089</fpage>&#x2013;<lpage>D1095</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1100</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: a Single-Centered, Retrospective, Observational Study</article-title>. <source>Lancet Respir. Med.</source> <volume>8</volume> (<issue>5</issue>), <fpage>475</fpage>&#x2013;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeom</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>S. K.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Anti-arthritic Effects of Ephedra Sinica STAPF Herb-Acupuncture: Inhibition of Lipopolysaccharide-Induced Inflammation and Adjuvant-Induced Polyarthritis</article-title>. <source>J. Pharmacol. Sci.</source> <volume>100</volume> (<issue>1</issue>), <fpage>41</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1254/jphs.fp0050637</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu R</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Computational Screening of Antagonists against the SARS-CoV-2 (COVID-19) Coronavirus by Molecular Docking</article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>56</volume> (<issue>2</issue>), <fpage>106012</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106012</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu S</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Network Pharmacology-Based Analysis of the Role of Traditional Chinese Herbal Medicines in the Treatment of COVID-19</article-title>. <source>Ann. Palliat. Med.</source> <volume>9</volume> (<issue>2</issue>), <fpage>437</fpage>&#x2013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.21037/apm.2020.03.27</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Oxyberberine Prevented Lipopolysaccharide-Induced Acute Lung Injury through Inhibition of Mitophagy</article-title>. <source>Oxid. Med. Cel Longev.</source> <volume>2021</volume>, <fpage>6675264</fpage>. <pub-id pub-id-type="doi">10.1155/2021/6675264</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>